Biointron Launches RushData, an Integrated Platform for AI-Driven Antibody Discovery with 1-Day CHO Expression

• 1-day CHO expression for data generation in days, not weeks, for standardized, structured datasets ready for AI/ML-driven design
• Custom workflows for targets and modalities, with 3,000+ molecules per batch processed in parallel
• Identify liabilities early with developability assessments to reduce late-stage failure and downstream risk

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biointron Biological USA Inc. ("Biointron"), a leading contract research organization for antibody discovery, expression, and optimization, has launched RushData. RushData is an integrated service platform designed to support the growing demands of AI- and machine learning-driven antibody discovery for global pharma and biotech organizations.

As computational antibody design continues to accelerate, AI and ML models are now able to generate hundreds to thousands of candidate antibody sequences in a single design cycle. But while sequence generation has scaled rapidly, experimental validation workflows are often fragmented, with expression, binding characterization, and developability testing performed separately across multiple steps or providers. This traditional approach can take 3-4 weeks or longer, slowing iteration and creating a major bottleneck in design-build-test-learn cycles.

RushData was developed to close this gap.

Built around Biointron’s 1-day transient CHO expression system, RushData enables researchers to move from antibody sequence submission to high-quality experimental data in days. The platform integrates antibody expression, binding analysis, and optional early developability profiling into a single standardized workflow, generating structured datasets that are well suited for AI/ML model training, validation, and optimization.

Designed for speed, scale, and therapeutically relevant data

RushData leverages CHO cells, the industry gold standard for therapeutic antibody expression, to produce data that is more predictive of downstream performance. CHO-based expression supports human-like post-translational modifications, proper protein folding, and clinically relevant developability characteristics.

RushData can support 3,000+ molecules per batch in parallel, with standardized workflows and structured outputs designed for both scientists and machine-readable AI pipelines.

Key advantages of RushData include:

• 1-day expression with CHO cells for rapid iteration and screening with custom workflows for targets and modalities
• Standardized, structured AI/ML-ready data from processing 3,000+ molecules per batch in parallel
• Binding characterization using BLI and/or SPR, integrated directly with expression and purity data
• Early developability profiling in selected packages, including:
  • Differential scanning fluorimetry (DSF) for thermal stability
  • AC-SINS for self-interaction behavior
  • Polyspecificity reagent binding (PSR-BVP) for polyreactivity

Flexible service packages

RushData is available through multiple service options tailored to different stages of antibody discovery:

• Basic – Rapid Screening
  Expression, titer, and affinity testing
• Standard – Binding Characterization
  Expression, concentration, cGE, and affinity testing
• Premium – Developability Profiling
  Includes early developability assessments with binding characterization

With more than 14 years of experience, service to 3,000+ biopharma companies worldwide, and deep expertise in antibody production and characterization, Biointron continues to expand its platform capabilities to meet the evolving needs of modern biologics discovery.

To learn more about RushData, visit https://www.biointron.com/rushdata or contact Biointron at [phone].

About Biointron

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies. From gene sequence to purified antibodies, our production only takes 2 weeks — and with RushData, our AI antibody wet lab validation service, computational predictions become experimentally confirmed candidates at high throughput. We have delivered tens of thousands of recombinant antibodies for more than 3,000 biotech and pharma companies worldwide.